GP
BIO icon

Greenline Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Greenline Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$487 – 186
2025
Q1 		$487 Buy
+2
New +$602 ﹤0.01% 472

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $8.09B AUM 21.95% 1-Year Est. Return

Greenline Partners's BIO Position: Q2 2025 in Review

Greenline Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 2 shares — an estimated $487 sold.

Greenline Partners first reported a position in BIO in Q1 2025 and held it in 1 quarter. The position peaked at $487 in Q1 2025. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

  • Greenline Partners reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
  • Greenline Partners sold 2 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $487.
  • Greenline Partners first reported a position in Bio-Rad Laboratories Class A in Q1 2025 and held it in 1 quarter.
  • Greenline Partners's Bio-Rad Laboratories Class A position peaked at $487 in Q1 2025.
  • 384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Greenline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.